Clinical Trials
6 trialsNCT04955743 2026-06-04
Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma
Yale University
Phase 2 Terminated
NCT05064280 2026-04-16
Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT07011849 2025-08-13
Study of Lenvatinib Plus Pembrolizumab in IO Refractory mRCC Patients With Brain Metastases
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT04729348 2025-07-25
Pembrolizumab And Lenvatinib In Leptomeningeal Metastases
Massachusetts General Hospital
Phase 2 Terminated
NCT02592356 2024-03-05
Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer
M.D. Anderson Cancer Center
Phase NA Completed
NCT03008369 2024-02-20
Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery
Mayo Clinic
Phase 2 Completed